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Abstract
Just over half of publicly funded trials recruit their target sample size within the planned study
duration. When recruitment targets are missed, the funder of a trial is faced with the decision of either
committing further resources to the study or risk that a worthwhile treatment effect may be missed
by an underpowered final analysis. To avoid this challenging situation, when there is insufficient prior
evidence to support predicted recruitment rates, funders now require feasibility assessments to be
performed in the early stages of trials. Progression criteria are usually specified and agreed with the
funder ahead of time. To date, however, the progression rules used are typically ad hoc. In addition,
rules routinely permit adaptations to recruitment strategies but do not stipulate criteria for evaluating
their effectiveness. In this paper we develop a framework for planning and designing internal pilot
studies which permit a trial to be stopped early if recruitment is disappointing or to continue to
full recruitment if enrolment during the feasibility phase is adequate. This framework enables a
progression rule to be pre-specified and agreed upon prior to starting a trial. The novel two-stage
designs stipulate that if neither of these situations arises, adaptations to recruitment should be made
and subsequently evaluated to establish whether they have been successful. We derive optimal
progression rules for internal pilot studies which minimize the expected trial overrun and maintain a
high probability of completing the study when the recruitment rate is adequate. The advantages of
this procedure are illustrated using a real trial example.
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1 Introduction
Many randomised controlled trials (RCTs) struggle to recruit their target sample size within the planned
study duration1;2. Delays to patient recruitment increase costs and hold up clinical research, with the risk
that new research questions will arise before a study can report its findings. Furthermore, trials missing
their recruitment targets will be underpowered to detect clinically relevant treatment effects, meaning
efficacious treatments may be wrongly abandoned for futility. A review of a cohort of UK publicly-funded
multi-centre clinical trials recruiting between 1994-2002 found that only 31% of trials met their original
enrolment target and 45% failed to reach even 80% of this figure3. Recruitment difficulties persisted in
a similar cohort of trials recruiting between 2002-2008, with 45% of trials missing their target sample
size. Almost half of the cohort (45%) were awarded either a time extension, additional funding, or both,
although only 55% of trials receiving this additional support reached their sample size target2.
Since there is a limited amount of funding available for research, competing projects must be
prioritised. Public funding bodies and commercial enterprises will want to maximise the value of the
research portfolio they support, diverting funding away from trials unlikely to meet their objectives on
budget and on time, to projects that are. Public funders are now paying closer attention to recruitment
and require feasibility assessments in cases where there is insufficient evidence before a trial begins to
support predicted recruitment rates. Such assessments can be reliably made in the early stages of a trial:
recruitment rates in the first two months of a trial have been found to be correlated with the proportion
of the recruitment target eventually accrued4. The UK National Institute for Health Research (NIHR)
expects all trials funded by its Health Technology Assessment Programme which incorporate an internal
pilot study to pre-specify an enrolment target for the pilot phase5. If this target is not met, investigators
must propose remedial steps to boost accrual and if no suitable modifications can be identified, funding
may be withdrawn. The pilot phase of these trials can be viewed as a ‘probationary period’ which enables
funders to screen out those studies for which the recruitment rate is so low that allowing enrolment to
continue to completion would result in a lengthy overrun.
Designs for internal pilot studies used to refine sample size calculations are well established6;7. In
contrast, the design of internal pilot studies to demonstrate the operational feasibility of a trial has
received little attention. Lee8 derives a target recruitment rate and interim minimum recruitment goals
which ensure that the final accrual target is met with high probability under the target recruitment rate.
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Gajewski et al.9 suggest abandoning an on-going trial if there is a high posterior predictive probability
that the final analysis will be severely underpowered, but do not propose any concrete designs. Jiang et
al.10 propose a similar criterion, abandoning a trial if the 95% posterior predictive interval for the time
to complete recruitment excludes 1.25 times the planned trial duration assuming recruitment follows a
homogeneous Poisson process. In our experience, ad hoc designs tailored to trials on a case-by-case basis
are typically used to monitor recruitment in practice: see, for example, the NERVES trial11, a multi-centre
RCT in sciatica, about which more detail is given in Section 5. In addition, progression rules often permit
adaptations to recruitment strategies without imposing criteria for determining their effectiveness.
To address these shortcomings, we formulate recruitment progression rules for internal pilot studies
incorporating up to two feasibility assessments. The framework proposes that these rules should be agreed
upon prior to the start of recruitment since this will reduce uncertainty for both funders and trialists. At
the first analysis, decisions are based on the total number of patients enrolled since the trial opened. Rules
recommend progression to the main trial if this total is promisingly high, and recommend abandoning
the trial for operational futility if it is inadequate. For intermediate outcomes, investigators must make
adaptations to boost recruitment and the effectiveness of these is evaluated at a second analysis based
on the number of patients enrolled since the first assessment. At this second analysis, a final decision is
taken on whether to progress with recruitment or abandon the trial. Predicting recruitment into a clinical
trial is a complex task. As a means of deriving enrolment targets that can be specified and discussed
with the funder ahead of time, we formulate optimal progression rules which minimise the average
expected overrun of a trial past its planned duration under a pragmatic model for patient and centre
accrual. We acknowledge that departures from this model may occur when the trial is conducted which
will imply that properties of optimal rules are not attained exactly. Nevertheless, the proposed framework
represents a general statistical approach to formulating progression criteria; devising these ahead of time
enables the funder to decide whether or not they agree with the proposed criteria before the trial begins.
Furthermore, in contrast to ad hoc rules, the proposed progression criteria are certain to be optimal in at
least one instance. We will investigate the impact of deviations from assumptions on the properties of our
proposed progression rules and show that designs remain efficient if departures are small. Pre-specified
progression criteria will still prove useful even when unforeseen events external to the trial occur since
the planned rule will provide a sensible and efficient starting point which can be adapted.
In Section 3, we define our new two-stage designs for internal pilot studies, before moving on to
derive optimal versions in Section 4. Applications to the NERVES trial are considered in Section 5. The
optimal timings of feasibility assessments is considered in Section 6, and the article concludes with a
brief discussion.
2 Illustrative example
The NERVES (NErve Root block VErsus Surgery) trial (ISRCTN number: ISRCTN04820368) funded by
the NIHR is a multi-centre RCT intended to compare the effectiveness of transforaminal epidural steroid
injection with surgery for the treatment of sciatica11. The primary clinical outcome is the Oswestry
Disability Questionnaire score at 18 weeks, assumed to be normally distributed. The trial is currently
open to recruitment. A total of 200 patients are required to have 90% power to detect a standardised
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effect of 0.5 at the two-sided 5% significance level allowing for a 10% loss to follow-up.
Based on early feasibility work it is estimated that six centres will open to enrolment and 30 patients
can be recruited per centre per year. These figures were derived from clinicians reviewing the number of
eligible patients and positing potential consent rates. Prior uncertainty about recruitment parameters was
enough to prompt the trial investigators to design the first phase of the NERVES trial as an internal pilot
study but not so much as to require an external pilot. The pilot phase will target two centres. This number
was chosen on pragmatic grounds: targeting two centres means that a specialist unit and a non-specialist
referral unit can be opened, but this number avoids committing too many resources to a trial that could be
abandoned for operational futility. While the pilot phase is underway, the remaining four centres will be
initialised so that they can open immediately upon progression to the main trial. Progression will depend
upon several criteria such as satisfactory rates of accrual, consent and treatment switching, although
for present purposes we will focus only on the recruitment criterion. Let N represent the total number
recruited across both sites during the 6-month pilot phase. The recruitment progression rule states that:
If N ≥ 30 Progress to complete recruitment using current enrolment strategies.
Otherwise Develop strategies to boost recruitment and progress incorporating
these adaptations.
(NERVES)
Note that while the NERVES internal pilot does not stipulate a stopping rule for recruitment, it does
incorporate stopping rules for other criteria. Under the assumed recruitment rate and centre opening
times, the expected time needed to recruit 200 patients is 17.3 months. In what follows we will use the
NERVES trial and its set-up to illustrate how optimal progression rules can be applied and their operating
characteristics.
3 Progression rules for internal pilot studies monitoring recruitment
3.1 Two-stage designs for internal pilot studies
Consider a multi-centre RCT designed to compare the relative efficacy of two treatments labelled A
and B. Let θ measure the advantage of A over B. Suppose that the trial’s primary objective is to
test H0 : θ = 0 against θ 6= 0 with type I error rate α. Using recruitment as a surrogate for feasibility
tacitly assumes that power depends on sample size or, more formally, that Fisher’s information for θ is
determined by sample size. Indeed, this does hold for many different data types, for example, when the
primary endpoint is a continuous, binary, ordinal or count variable12. Let nmax denote the total sample
size needed to satisfy the power criterion.
Suppose early feasibility work identifies C centres from which eligible patients can be recruited. Let t
represent the time (in months) since commencement of recruitment, so that recruitment begins at calendar
time t = 0. Furthermore, let tp denote the initial estimate of the time needed to complete recruitment used
to inform funding requests where tp will be chosen to ensure that the trial’s findings will be relevant upon
its conclusion. The first stage of the RCT will be conducted as an internal pilot study, where progression
to the main trial is assured if early recruitment is sufficient. We consider two-stage designs for the internal
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pilot, scheduling feasibility assessments at calendar times t1 and t2. Let N1 denote the total number of
patients recruited over the interval [0, t1] and letN2 denote the total number of patients recruited over the
interval [t1, t2]. We propose designs with progression rules of the form:
At assessment 1:
If N1 ≥ u1 Progress to complete recruitment using current enrolment strategies.
If N1 ≤ l1 Stop recruitment for operational futility.
Otherwise Modify enrolment strategies and proceed to feasibility assessment 2.
At assessment 2:
If N2 ≥ u2 Progress to complete recruitment using modified enrolment strategies.
Otherwise Stop recruitment for operational futility.
(1)
Rule (1) is defined tacitly assuming that recruitment will stop immediately once nmax patients have
been enrolled. If this target is reached during the pilot phase, ‘progression’ is unnecessary and the
final efficacy analysis can be conducted at once. Setting l1 = −1 in (1) implies that early stopping
for operational futility is not permitted at the first interim analysis. Meanwhile, setting u1 ≥ nmax
implies that progression to the main trial at time t1 is not permitted, since progression is allowed only
when it is unnecessary. Similarly, all choices of u2 with u2 ≥ nmax − u1 imply that progression is
not permitted at time t2. Therefore, we can restrict attention to rules with −1 ≤ l1 < u1 ≤ nmax and
0 ≤ u2 ≤ nmax − u1.
Adaptations to enrolment strategies introduced after the first feasibility assessment can take any form.
Potential changes include widening the trial eligibility criteria; altering the means of communication with
patients; offering incentives; and staff training13;14. One could also open additional centres, although we
defer consideration of this adaptation until the Discussion. In view of the variety of possible adaptations,
strong assumptions would be needed to relate the recruitment rate incorporating adaptations to the
recruitment rate without them. Therefore, if the internal pilot study continues to a second stage, the
effectiveness of the modifications is assessed on the basis of the number of patients recruited between
times t1 and t2 only.
The timings of interim analyses also require particular attention. A careful choice of t1 will ensure that
this assessment time is long enough to allow recruitment to get up to speed before the first assessment
is conducted. If adaptations are recommended, it will take some time for changes to be communicated
to centres and become embedded in practice. Assessment time t2 must be carefully chosen to be long
enough to allow adaptations to take effect but not so long as to lose efficiency if they are ineffective.
3.2 A proposal for centre opening times
For ease of explanation, we propose designs for internal pilot studies which stipulate that centres should
open to recruitment in up to three ‘waves’, as illustrated in Figure 1. However, in Appendix B of the
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Supplementary Materials accompanying this manuscript, we describe how progression rules can be found
under more complex models for centre opening times. Whilst in principle our designs could be formulated
for the case that all C centres participate in the internal pilot, following the NERVES trial we prefer to
stipulate that c1 < C centres should participate in the first phase of the pilot. We assume that all c1 centres
will be ready to begin recruiting at time t = 0. During the period [0, t1], the remaining (C − c1) centres
are initialised so that they can open at time t1 should the pilot study progress to the main trial at this
earliest opportunity. If, however, the pilot phase is extended at time t1, we stipulate that an additional
c2 − c1 < C − c1 centres must open and adaptations to recruitment are rolled out simultaneously across
the c2 centres recruiting from time t1 onwards. If the pilot study progresses to the main trial at the
second feasibility assessment, the remaining (C − c2) centres must open at time t2. The impact on design
properties of departures from the recruitment pattern in Figure 1 is assessed in Section 5.4.
Several aspects of our proposed designs merit further discussion. Our preference to involve only a
subgroup of centres in the pilot phase reflects current standard practice when there is uncertainty about a
trial’s operational feasibility: see, for example, the protocols of the NERVES11, CASPER15 and FACT16
trials. Our preference arises because opening centres is not without cost. Staggering opening times reflects
a compromise between our wish to open all sites as quickly as possible and our desire to minimise
our regret at wasting resources on a trial that is later abandoned for inadequate accrual. Alternatively,
if adaptations to recruitment are recommended at time t1, the decision to open only a subset of the
(C − c1) newly initialised centres at time t1 may simply reflect the fact that it will be impractical to roll
out adaptations across a large number of centres simultaneously. Having said that, as noted above, our
designs could in principle be derived setting c1 = c2 = C.
3.3 Choice of pilot centres
So that it is possible to extrapolate from early recruitment trends to make reliable judgements about
the feasibility of the main trial, the first groups of c1 and c2 centres must be carefully chosen to be
representative of the C centres that will eventually participate in the trial. Here representative means
similar in terms of the overall average monthly recruitment rate. We do not have in mind a formal
quantitative approach for selecting centres to participate in the internal pilot. Instead, we suggest that
pilot centres should be selected on the basis of factors thought a priori to be predictive of centre-specific
recruitment rates. For example, if accrual rates are expected to be higher in specialist centres than mixed
care settings and if the former are to comprise around half of all C centres, then specialist centres should
also comprise 50% of the sites chosen to participate in each stage of the internal pilot. Deliberately
choosing all pilot centres to be specialist centres would, in this example, bias upwards interim estimates
of the average monthly recruitment rate, with the risk that an infeasible trial would be allowed to progress.
For this reason, the NERVES pilot centres are a mixture of specialist and non-specialist referral units.
3.4 Modelling individual patient accrual
Properties of progression rule (1) are evaluated under a pre-specified model for patient accrual in a
multi-centre trial. Below we review models for individual patient accrual that have been suggested in
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Figure 1. Opening times of C centres participating in a RCT incorporating progression rule (1).
the literature, and our own pragmatic proposal.
3.4.1 A review of existing models for patient accrual Systematic reviews of the literature17–19 have
found that stochastic recruitment models can take the form of a Poisson process; a two-state Markov
model; a first-order autoregressive time-series model; or assume differences between the observed and
expected cumulative numbers recruited follow a Brownian motion. Lee8 and Senn20 were amongst the
first authors to propose a Poisson model for recruitment, where this will be reasonable if one can assume
that patients enter a trial independently of one another and there is a negligible probability of two patients
arriving simultaneously. Variations proposed for modelling the total number of patients recruited include
a homogeneous Poisson process9;10; a contagious Poisson model where the recruitment rate for the
interval (ti, ti+1) is taken to be the total number of patients recruited up to time ti divided by ti 8; a
Poisson process with piecewise constant rate over the time interval of interest21; and a non-homogeneous
Poisson process with time-varying rate modelled using cubic B-splines22. Methods9;10;21;22 model the
total number recruited by aggregating across centres and do not incorporate information on centre-
specific recruitment rates. However, hierarchical models accommodating centre-specific information
have been proposed which assume that recruitment into each centre, once open, follows a homogeneous
Poisson process with rate sampled from a Gamma23;24 or decentred-Pareto25 distribution.
To derive prior predictions from recruitment models (for example, forecasts of the time needed
to complete recruitment), initial guesses at model parameters must be deduced either from relevant
completed trials or expert opinion26, although the latter may be challenging unless model parameters
have a direct interpretation. Once a trial is underway, interim predictions can be derived from recruitment
models fitted using maximum likelihood estimation21; using Bayes theorem to update prior distributions
elicited from expert opinion9;10; or using an empirical Bayes analysis23, whereby a Bayesian approach is
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taken to predict the remaining recruitment time by substituting prior hyperparameters with maximum
likelihood estimates derived from the observed trial data. Assuming a Poisson-Gamma hierarchical
recruitment model, Anisimov24 proposes using accumulating trial data to forecast whether poor
performing centres will recruit further patients in a future time interval and adjusts the number of trial
centres to ensure accrual can be completed by a specified deadline with high probability.
3.4.2 A proposal for a pragmatic model for patient accrual We formulate progression criteria based
on relatively simple, pragmatic, statistical recruitment models that can be specified in advance, rather
than rely on complex models whose goodness-of-fit may be difficult to verify even in the early stages
of the trial. Specifically we evaluate properties of our proposed progression rules assuming all centres
recruit to capacity and there is no competition between centres for patients. Furthermore, we assume that
recruitment into each centre follows a Poisson process so that total recruitment into the trial, aggregating
across all centres, also follows a Poisson process with monthly rate Λ(t) at time t. In the absence of
adaptations, recruitment into centre i occurs at a constant monthly rate λi, for i = 1, . . . , C. Let λ =
(1/C)∑Ci=1 λi represent the average monthly recruitment rate per centre. Since a representative sample
of centres is selected to participate in the pilot phase, it is reasonable to assume that Λ(t) = c1λ for
0 ≤ t ≤ t1, and if the study progresses to the main trial at the first feasibility assessment Λ(t) = Cλ, for
t > t1. However, if the pilot study continues to a second stage, adapting enrolment strategies will lead to
a shift in the average monthly recruitment rate per centre. Let η denote the fraction increase in λ effected
by the adaptations. Then, Λ(t) = c2λ(1 + η) for t1 < t ≤ t2, and this increases to Λ(t) = Cλ(1 + η) for
t > t2 if progression is recommended at the second feasibility assessment. In what follows, a Bayesian
approach will be adopted to accommodate prior uncertainty about λ and η.
3.5 Properties of trials incorporating internal pilots
Several properties are of interest when evaluating recruitment progression rules of the form (1). Define
a trial’s operational power as the probability of completing recruitment. Assuming that recruitment is
always completed once progression has been recommended, this can be said to occur if either: a) nmax
patients are enrolled during the internal pilot study; or b) the criterion for progression defined in (1) is
met at an interim analysis. Therefore, for fixed λ and η, operational power is
pr{N1 ≥ u1}+ pr{l1 < N1 < u1, N2 ≥ min{u2, nmax −N1}} (2)
= pr{X ≥ u1}+
u1−1∑
n1=l1+1
pr{X = n1}pr{Y ≥ min{u2, nmax − n1}}
whereX and Y are Poisson distributed random variables with parameters c1λt1 and c2λ(1 + η)(t2 − t1),
respectively. Similarly, the probability of progression to the main trial at t2 is
u1−1∑
n1=l1+1
pr{X = n1}pr{u2 ≤ Y < nmax − n1},
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assuming that progression is unnecessary if nmax or more patients have been recruited by time t2.
Let T represent the trial duration (in months), where the trial ends when recruitment has been
completed or stopped early for operational futility. In Supplementary Appendix A, we show that for
fixed values of λ and η the expected overrun of a trial beyond time tp is
E [max{0, T − tp};λ, η] =
∫ ∞
tp
(t− tp)
nmax−1∑
n1=u1
pr{X = n1}h(t− t1;nmax − n1, Cλ) dt
+
∫ ∞
tp
(t− tp)
u1−1∑
n1=l1+1
nmax−n1−1∑
n2=u2
pr{X = n1} pr{Y = n2}h(t− t2;nmax − n1 − n2, Cλ(1 + η)) dt ,
(3)
where h(z; a, b) is the probability density function (pdf) of a Gamma(a, b) random variable given by
h(z; a, b) =
baza−1 exp{−bz}
Γ(a)
, z ≥ 0.
4 Optimising recruitment progression rules
4.1 Optimal design criteria
When choosing the boundaries (l1, u1, u2) of an internal pilot study, we stipulate two properties designs
must possess:
(D1) Designs should recommend adaptations to recruitment with probability at most κ when λ is
promisingly large.
(D2) Designs should achieve operational power not less than 1− ρ under the lowest promising values
of λ and η, denoted by λmin and ηmin.
Through desideratum (D1), we calibrate designs to limit the probability of requiring adaptations when
the trial would otherwise come to a timely conclusion; here we take a promisingly large value of λ to
be λ˜, the prior best estimate. Power criterion (D2) reflects a wish to complete recruitment and conduct
a high powered test of efficacy whenever feasible. We offer some general guidance on setting κ and ρ.
For reasons of science and ethics, the probability of completing a feasible trial should be high, so that
setting ρ = 0.1 or 0.2 will, in general, be appropriate. Meanwhile, the most suitable value for κ will
vary from trial to trial depending on the anticipated cost and difficulty of adapting recruitment processes.
However, a value for κ between 0.1 and 0.4 will be appropriate in many cases; larger than conventional
risks of incorrect decision making will be acceptable since making unnecessary adaptations may be an
inconvenience but will not jeopardise patient safety or trial integrity. In all future evaluations of methods,
we set κ = 0.15 and ρ = 0.1.
Letting η˜ represent the prior best guess at η, one approach to setting operational power would be
to specify it under λ˜ and η˜. However, to guard against using excessively optimistic prior guesses at
parameters, we consider whether smaller values are consistent with a tolerable risk of a significant
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overrun. To this end, let T1 represent the time (in months) to completion of recruitment under the design
setting l1 = −1 and u1 = 0, so that the internal pilot study progresses to the main trial at t1 unless
recruitment has already been completed. Furthermore, let T2 denote the time (in months) to completion of
recruitment under the design setting l1 = −1, u1 = nmax and u2 = 0. Then, define λL(t1) and ηL(t1, t2)
as solutions to
pr{T1 ≥ νtp;λ = λL(t1)} = ζ1 (4)
pr{T2 ≥ νtp;λ = λL(t1), η = ηL(t1, t2)} = ζ2. (5)
The calculations needed to evaluate the probabilities in Equations (4)-(5) are described in Supplementary
Appendix A. Since ζ1 and ζ2 should represent tolerable risks of a significant overrun, we suggest setting
these parameters to values between 0.05 - 0.2. Meanwhile, previous authors have taken a 25% overrun to
be significant10. Therefore, in future evaluations of methods we set ν = 1.25, ζ1 = 0.05 and ζ2 = 0.1. We
set ζ2 > ζ1 because trials always progressing at time t2 rather than t1 take longer to complete due to the
staggered opening times of centres. We write λL(t1) and ηL(t1, t2) to emphasise the dependence of these
parameters on t1 and t2. This arises because of the impact of t1 and t2 on the opening times of centres:
earlier scheduling of assessments means recruitment can potentially be rolled out across all C centres
sooner so that smaller values of λ and η are associated with acceptable risks of a significant overrun. We
refer to λmin = min{λ˜, λL(t1)} and ηmin = min{η˜, ηL(t1, t2)} as the lowest promising values of λ and
η, respectively, taking minimums to ensure we consider values both promising and realistic. We specify
a design’s operational power at λ = λmin and η = ηmin.
In the class of designs with desiderata (D1) and (D2), we seek the progression rule which we expect to
minimise the overrun of the trial past time tp. Rather than minimiseE[max{0, T − tp};λ, η] for particular
values of λ and η, we minimise a Bayesian version of this criterion, integrating E[max{0, T − tp};λ, η]
with respect to a joint prior density for (λ, η) representing uncertainty about these parameters. Rules
minimising this Bayesian criterion can be thought of as minimising the average expected overrun of the
trial. We characterise uncertainty about λ and η as independent priors derived from (possibly discounted)
expert opinion. Strategies for eliciting expert prior opinion on λ and η can be found in Supplementary
Appendix C. We acknowledge that there will be an element of subjectivity to individuals’ answers to
the proposed elicitation questions. However, these opinions will often be based on relevant data. In the
UK public sector, almost all funding proposals will be informed by early feasibility work: centres set
to participate in the trial will complete screening logs to record the number of patients meeting trial
eligibility criteria over a number of weeks. These figures are then discounted to take into account likely
consent rates. Experts will be able to draw on these data, as well as their own experiences of similar trials,
when stating their opinions. Alternatively, if there was substantial experience of conducting studies in a
disease, priors for λ and η could be derived from historical recruitment data by performing a meta-
analysis of completed trials26.
Gajewski et al.9 model opinion on the expected interarrival time of a Poisson recruitment process as an
inverse-gamma distribution. We adopt this approach and model prior opinion on λ as a Gamma(α1, β1)
distribution. Considering the elicitation of opinion on η, we note that investigators are likely to have
some idea a priori of the nature of the adaptations to recruitment that would be feasible in their trial.
For example, the nature of the intervention may preclude widening the eligibility criteria but it may
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be deemed possible to refine the screening process. Experts’ prior experiences with previous trials will
inform their opinions on the likely impact of such modifications. Of course there is a risk that, once
implemented, adaptations would prove ineffective at increasing the average monthly recruitment rate per
centre (indeed, modifications investigators are certain would be effective should be incorporated from the
outset of the trial if within resource constraints). To capture opinion on this risk we model prior beliefs
for η as a mixture distribution, placing weight ω on the scenario that η = 0 and weight (1− ω) on the
scenario that η is sampled from a Gamma(α2, β2) distribution. Given these priors, we seek the internal
pilot design with desiderata (D1) and (D2) minimising the average expected overrun
F = ω
∫ ∞
0
E [max{0, T − tp};λ, η = 0]h(λ;α1, β1)dλ
+ (1− ω)
∫ ∞
0
∫ ∞
0
E [max{0, T − tp};λ, η]h(η;α2, β2)h(λ;α1, β1) dη dλ.
4.2 Finding optimal progression rules
We use a direct search to find the triple (l?1, u
?
1, u
?
2) minimising F in the class of rules with desiderata
(D1) and (D2). The computational cost of such a search is manageable because we only need to evaluate
the average expected overrun for a subset of designs. To see this, first note that we can restrict our search
to the subset of triples with −1 ≤ l1 < nmax and l1 < u1 ≤ nmax satisfying pr{l1 < N1 < u1; λ˜} ≤ κ.
Suppose la1 and u
a
1 are boundary values satisfying this constraint. Then, fixing l1 = l
a
1 and u1 = u
a
1 ,
equation (2) implies that as u2 increases, operational power at λ = λmin and η = ηmin decreases due
to the more stringent criterion for progression imposed at the second interim. Turning our attention
to the expected trial overrun, we see that the integrand of the RHS integral in (3) is the sum of non-
negative terms. Since fewer terms are included in this summation as u2 increases, it follows that for any
configuration of λ and η, E[max{0, T − tp};λ, η] is a decreasing function of u2, which in turn implies
that F must be a decreasing function of u2. Thus, setting u2 equal to the largest integer τ ≤ nmax for
which operational power at λ = λmin and η = ηmin is not less than 1− ρ, it follows that the design
defined by (la1 , u
a
1 , τ) minimises F in the class of rules satisfying constraints (D1) and (D2) with l1 = l
a
1
and u1 = ua1 . Repeating this step across all pairs (l1, u1) satisfying constraint (D1) yields the globally
optimal design we seek.
Finding an optimal design requires repeated evaluations of the average expected overrun of a trial,
which itself requires evaluation of two- and three-fold integrals. We evaluate integrals numerically
in R27 using the cubature package28. Setting c1 = 2, c2 = 4, C = 6, t1 = 6, t2 = 12, nmax = 200,
λmin = 2.1, ηmin = 0.115, it takes 130 minutes on a 2.9 GHz Intel Core i7 processor to find the
progression rule minimising F with desiderata (D1) and (D2). Computing time is reduced to 10.1
minutes if the optimal rule is found evaluating F using 10 million simulations. In the examples we
have considered, values of F obtained using numerical integration and simulation have been consistent
to 2 decimal places. Furthermore, the impact of Monte Carlo error on comparisons of rules can be
reduced by basing simulations for different designs on the same sequence of pseudo-random numbers.
This less accurate (but quicker) computational approach will likely suffice when the aim is to consider
many different testing scenarios in order to develop a broader understanding of the impact of settings on
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properties of rules.
4.3 Specifying an internal pilot in the trial protocol
To draw together the ideas presented thus far, we make some recommendations on how to specify the
design of a two-stage internal pilot study in a trial protocol. First, the protocol should name the c1 and
c2 centres that will be targeted in each pilot phase and give a brief justification for why these sites are
considered to be representative of the C centres that will eventually participate in the trial. The protocol
should also list the timings of the interim analyses, t1 and t2, and the decision criteria that will be applied
at each. A complete description of the progression criteria would also define the following parameters:
a) the constraints (D1) and (D2), including the values of λ and η at which operational power and the
maximum probability of recruitment adaptations are specified; b) the Bayesian optimal design criterion
F and the design priors for λ and η under which F is derived. This level of detail will ensure that the
progression rule is reproducible. Properties of the design should also be characterised, both under the
anticipated centre opening times and under other realistic accrual patterns. Key operating characteristics
include the probability of recommending recruitment adaptations, the probability of progressing to full
recruitment, expected trial overrun, and the risk of a significant overrun.
5 Application to the NERVES trial
5.1 Properties of the original NERVES progression rule
We begin by considering the single-stage ad hoc progression rule implemented in the NERVES trial.
Properties of Rule NERVES are evaluated given that two centres will participate in the pilot phase and
the four remaining centres will open immediately at 6 months. This rule satisfies design criterion (D2)
because it does not permit stopping for operational futility. However, it violates criterion (D1) since it
recommends adaptations with probability 0.476 when λ = 2.5.
To illustrate how prior distributions for λ and η might be derived for the NERVES trial, recall that
the prior best guess at λ was 2.5: this value will be used as λ˜ for the purposes of specifying design
constraints (D1) and (D2). Furthermore, suppose that expert opinion states there is a 75% chance that
λ ≤ 3. However, since investigators may be overly optimistic about recruitment, it may be preferable to
optimise progression rule (1) under a design prior formed by modifying elicited distributions so that
λ has a Gamma prior with mode shifted to the left of 2.5 (to 2) and variance preserved at α1/β21 ,
which gives λ ∼ Gamma(13.519, 6.260). A mixture distribution for η with weight 0.4 on η = 0 and
0.6 on η ∼ Gamma(2.900, 12.664) is implied by the opinion that there is an 60% chance that planned
adaptations to recruitment will be effective and the conditional beliefs that given η > 0, the most
likely value is η˜ = 0.15 and there is a 75% chance that η ≤ 0.3. These hypothetical opinions appear
feasible given the range of results reported by studies comparing strategies to improve recruitment in
RCTs13. Assuming these design priors for λ and η, the average expected overrun of the NERVES trial
is F = 2.807 months. We compare properties of the original NERVES progression rule with those of
optimal two-stage designs below.
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Figure 2. a) Probability of recommending adaptations to recruitment for Rules NERVES and localopt ; b)
Probability of progressing to the main trial at time t1 to complete recruitment for Rules NERVES and localopt ;
c) Conditional probability under Rule localopt of progressing to complete recruitment at time t2 given progress
to Stage 2 of the pilot study; d) Probability under Rule localopt of completing recruitment. All evaluations of
rules set c1 = 2, c2 = 4, C = 6, t1 = 6 and t2 = 12. Rule localopt is defined with (l1 = 17, u1 = 25, u2 = 48).
Contour plots have contours drawn at probability intervals of 0.1.
5.2 Optimal progression rules for the NERVES trial
We derive two-stage rules of the form (1) for the NERVES trial, preserving the time of the first
feasibility assessment as t1 = 6 months and fixing t2 = 12 months. We consider rules controlling the
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Figure 3. Properties of Rules NERVES and localopt : a) Expected number of patients recruited by time tp for
studies progressing to the main trial to complete recruitment; b) Probability that the trial duration exceeds tp by
more than 25%. All evaluations set c1 = 2, c2 = 4, C = 6, t1 = 6, t2 = 12, nmax = 200 and tp = 17.3.
Expected numbers recruited are based on 10 million simulations. Rule localopt is defined with
(l1 = 17, u1 = 25, u2 = 48).
maximum probability of recruitment adaptations at 0.1 when λ = 2.5. Operational power is stipulated
at λmin = min{2.5, λL(t1)} = 2.112 and ηmin = min{η˜, ηL(t1, t2)} = 0.115, where λL(t1 = 6) and
ηL(t1 = 6, t2 = 12) are found as solutions to Equations (4) - (5). Then, setting c1 = 2, c2 = 4, C = 6,
nmax = 200, we find the design minimising F under the Gamma(13.519, 6.260) prior for λ and mixture
prior for η defined above. This locally optimal rule, labelled ‘Rule localopt’, stipulates that if 17 or fewer
patients are recruited in the first 6 months of the trial, accrual must stop. If 25 or more patients are
recruited, the trial should progress to complete recruitment without modifications or further feasibility
assessments. Otherwise, if between 17 and 25 patients are recruited, adaptations are required and a second
feasibility assessment must be conducted at 12 months to evaluate their effectiveness. At the time of this
second assessment, if fewer than 48 patients have been recruited in the last 6 months, the trial must stop,
otherwise it must progress to complete recruitment incorporating changes to recruitment. The average
expected overrun of the trial under this design is F = 1.235 months.
Recall that T represents trial duration and assume a significant overrun occurs if T ≥ 1.25 tp.
Figures 2 and 3 compare properties of Rule NERVES with those of Rule localopt as the true average
monthly recruitment rate per centre, λ, varies. We see that the two-stage rule recommends modifications
to recruitment with lower probability than the single-stage Rule NERVES. Figure 3(b) highlights
further advantages of permitting early stopping for operational futility and of evaluating adaptations
to recruitment strategies. Specifically, for trials incorporating two-stage progression rules, the risk of a
significant overrun approaches 0 for extreme values of λ since in these scenarios the trial will almost
surely either stop early for operational futility, incurring no overrun, or progress to complete recruitment
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within tp months. However, since Rule NERVES does not permit early stopping, the risk of a significant
overrun under this rule quickly approaches 1 as λ falls below 2. Additionally, not evaluating the
effectiveness of recruitment adaptations means that if modifications are ineffective, under Rule NERVES
the trial would incur a large penalty in terms of an increased risk of a significant overrun. This penalty is
smaller for the two-stage design. Studying the risk curve for Rule localopt, we see that for λ < 1.906, the
risk of a significant overrun is greater when η = 0.115 than when η = 0 because when η = 0.115 there
is a greater probability of progressing at Stage 2 to complete recruitment rather than abandoning the trial.
The ordering of the risk curves is reversed for λ > 1.906 as trials progressing at Stage 2 become more
likely to complete accrual within 1.25 tp months. Comparing Figures 3(a) and 3(b), we see that for certain
pairs of λ and η, the risk of a significant overrun under Rule NERVES is greater than under Rule localopt
but we expect to recruit more patients by time tp. In these cases, the distribution of T has heavier tails
under Rule NERVES but the probability that T ≤ tp is greater because this single-stage rule recommends
adaptations with higher probability and rolls out accrual across all C centres after six months, whereas
this may be postponed until 12 months under the two-stage design.
Figure 4 evaluates the robustness of the efficiency of Rule localopt to a prior-data conflict: in this
scenario we may regret optimising the progression rule under priors for λ and η which place large
probability mass on parameter values inconsistent with the observed data. It is clear that the relative
efficiency of Rule localopt is poor when the true average monthly recruitment rate per centre, λ, lies
in the tails of the Gamma(13.519, 6.260) prior distribution used for optimisation. However, for values
of λ within the 50% central interval of (1.740, 2.521), the efficiency of Rule localopt is within 67% of
that of the locally optimal design for all values of η considered; for many pairs of parameter values, the
relative efficiency is within 20%. The robustness of the efficiency of Rule localopt to deviations from
the assumption that the average monthly recruitment rate per centre remains constant across the pilot and
main phases of the trial is examined in Supplementary Appendix D.
5.3 Impact of progression rules on efficacy testing
The attained error rates of the test of H0 will deviate from their nominal values if early stopping for
operational futility is permitted. For example, if we are permitted to test H0 only if the progression
criteria are met and accrual is completed, the overall type I error rate will be less than α because a trial
may be stopped early for operational futility without rejecting H0 in cases where it otherwise would
have gone on to commit a type I error. While we do not advocate adjusting the final efficacy analysis
for the possibility of early stopping for operational futility, we do recommend exploring the impact of
monitoring recruitment on a trial’s power ahead of time.
Table 1 quantifies what the impact of Rule localopt would be on the power and type I error rate
of the NERVES trial. Values of λ are indexed by the expected trial duration calculated as t1 + (nmax −
c1t1λ)/(Cλ). For present purposes we assume that all recruited patients are followed-up for their primary
endpoint (that is, there are no missing data), meaning that in the absence of feasibility testing NERVES
has 94.2% power to detect a standardised effect of 0.5 at the two-sided 5% significance level. When
Rule localopt is incorporated into the NERVES trial, power decreases when there is a non-negligible
probability of stopping early. If we permit efficacy testing only when the target sample size is met,
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Figure 4. Value of E[max{T − tp, 0};λ, η] attained by Rule localopt expressed as a percentage of the
minima attained by the locally optimal design. All locally optimal designs are derived setting c1 = 2, c2 = 4,
C = 6, t1 = 6, t2 = 12, nmax = 200 and tp = 17.3, and specifying operational power at λ = 2.1 and η = 0.115.
Contours are drawn at 101, 102, 105, 110, 120, 150 and 200% and at every 100 percentage points thereafter.
Table 1. Operating characteristics of an RCT incorporating Rule localopt when efficacy testing is: a) always
permitted on termination of the trial; and b) only permitted if nmax = 200 subjects are recruited. Properties
relate to a two-sided test of H0 : θ = 0 conducted setting α = 0.05, assuming data are normally distributed
and θ is a difference in means. Listed are attained two-sided type I error rates and power for detecting a
standardised effect of 0.5. The probability of early stopping is the probability of stopping for operational futility
at any feasibility assessment. All properties are calculated under η = 0.115 setting c1 = 2, c2 = 4, C = 6,
t1 = 6 and t2 = 12.
True average Testing scenario a) Testing scenario b) Probability E(N) when
accrual length Power Type I Power Type I stop early stop early
(months) Error Error
15.0 0.942 0.050 0.942 0.050 2.791 ×10−4 16.351
17.3 0.936 0.050 0.935 0.050 0.008 22.075
20.0 0.873 0.050 0.834 0.044 0.115 39.394
22.0 0.729 0.050 0.595 0.032 0.369 43.087
deviations in power and type I error rate increase as λ decreases. Losses in power are ameliorated and
the overall type I error rate preserved at its nominal level when efficacy testing is always permitted on
trial termination. However, losses in power still persist because efficacy tests are underpowered when
recruitment is abandoned before completion. Table 1 lists results for η = 0.115; increasing η leads to a
reduced probability of early stopping and thus smaller deviations in power.
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5.4 Robustness of optimal progression rules to deviations from recruitment
assumptions
In practice, centres must obtain ethics and R&D approvals before they can open to recruitment. We refer
to centres in receipt of these approvals as ‘initialised’. Unforeseen delays in obtaining approvals may
mean that centre opening times cannot follow the pattern envisaged in Figure 129. Such departures will
imply that properties of progression rules deviate from their pre-specified values. Let NI(t) denote the
total number of centres initialised after the trial has been open for t months. Supplementary Figure S1
illustrates centre opening times for the NERVES trial under progression rule (1) when
NI(t) = min{C, c1 + bγtc} for t ≥ 0, (6)
setting t1 = 6 and t2 = 12, and where γ is a constant reflecting the rate at which new centres are
initialised. Supplementary Appendix B describes how optimal versions of rule (1) are derived when
initialisation times follow model (6) with γ = 0.3 and γ = 0.5.
Supplementary Figure S2 assesses the robustness of properties of Rule localopt to delays in centre
openings. Small departures from the anticipated pattern imply deviations from design properties are also
small. If γ = 0.5 in model (6), the initialisation of centres is only marginally slower than was anticipated
when the internal pilot was designed: Rule localopt (l1 = 17, u1 = 25, u2 = 48) remains the optimal rule
for this modified pattern, with an average expected overrun of F = 1.330 months. If, however, γ = 0.3,
centres are much slower to open than was initially expected. If we had optimised the progression rule for
this accrual pattern, Rule localopt would no longer satisfy power criterion (D1) and instead the optimal
progression rule with desiderata (D1) and (D2) has boundaries (l1 = 17, u1 = 25, u2 = 35) and achieves
F = 2.242 months.
6 Impact of varying assessment schedules
So far we have followed the NERVES trial to assume that feasibility assessments will be scheduled at
six-monthly intervals. To explore the impact of varying the feasibility assessment schedule, we optimise
the interim assessment timings t1 and t2. In practice, these timings would typically be rounded to the
nearest month. With this in mind, we restrict our search for optimal times to integer pairs satisfying
the constraints pi1 ≤ t1 ≤ tp − pi1 and t1 + pi1 ≤ t2 ≤ tp. The interval pi1 must be long enough for our
assumption that all C centres will be ready to open by t1 = pi1 to be plausible. More generally, we believe
that designs with pi1 ≈ 0 would be impractical because: a) it would be difficult to justify stopping a trial
at the first interim analysis on the basis of very few data; and b) if adaptations are made to recruitment
processes at an interim analysis, pi1 must be long enough to allow centres to become familiar with new
trial procedures and begin recruiting at their optimal rate before the next feasibility assessment.
Considering the NERVES trial, we set pi1 = 4 along with c1 = 2, c2 = 4, C = 6, nmax = 200 and
tp = 17.3, and perform a direct search over pairs (t1, t2) satisfying our constraints. For each pair, we find
the progression rule with desiderata (D1) - (D2) minimising F under the design priors for λ and η defined
in Section 5.1. Operational power is specified at λ = min{2.5, λL(t1)} and η = min{0.15, ηL(t1, t2)},
where λL(t1) and ηL(t1, t2) are found as solutions to Equations (4) - (5). We find that the optimal
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assessment schedule is t1 = 4 and t2 = 12 months. All evaluations of F were performed using numerical
integration. The optimal rule for this analysis schedule, labelled ‘Rule globalopt’ is defined by (l1 =
7, u1 = 15, u2 = 66) and achieves F = 1.100 months. Setting λmin = min{2.5, λL(t1)} = 1.964 and
ηmin = min{0.15, ηL(t1, t2)} = 0.147, this rule has operational power 0.903 under λ = λmin and η =
ηmin, and recommends recruitment adaptations with probability 0.104 when λ = 2.5. Comparing Rules
localopt and globalopt in Figure 5 reveals the impact of conducting the second feasibility assessment
with more data. Figure 5(a) shows that as the true average monthly recruitment rate per centre tends
towards 1, the conditional probability of progression at the second assessment under Rule localopt is
slower to decrease than this probability under Rule globalopt. To explain this, recall that we model
N2 ∼ Pois(c2λ(1 + η)(t2 − t1)). Therefore reducing the length of the interval [t1, t2] means smaller
shifts in the location of the distribution of N2 result from varying λ or η. Thus Rule localopt is less
able than Rule globalopt to distinguish between promising and inadequate recruitment scenarios. Since
Rule globalopt is powered to complete recruitment under a lower value of λ, probabilities of completing
recruitment are larger than under Rule localopt. Thus, it follows that the risk of a significant overrun is
greater for Rule globalopt when the true value of λ is small.
7 Discussion
In this paper we have developed two-stage recruitment progression rules for internal pilot studies that
can be specified ahead of time and which permit early stopping for operational futility and the evaluation
of adaptations to recruitment procedures. These designs stipulate that centres should enter the trial in up
to three waves at times t = 0, t1 and t2. However, we have shown that our methods can be extended to
incorporate more complex models for centre opening times, for example, to accommodate non-constant
total recruitment rates during the intervals (t1, T ) and (t2, T ) which may arise if it is unreasonable to
stipulate that C centres should be initialised by the time of the first feasibility assessment.
Our proposed methods could be extended in several ways. For instance, it would be straightforward
to derive optimal progression rules minimising a different criterion to the average expected trial overrun;
suitable alternatives include the average risk of a significant overrun or a large percentile of the marginal
distribution of max{T − tp, 0}. Alternatively, our two-stage designs could be applied using different
(non-optimal but intuitive) criteria to set (l1, u1, u2). In particular, one alternative seems worthy of further
consideration, motivated by the fact that the most controversial outcome of an internal pilot study would
be to recommend early stopping at the first interim analysis. An intuitive approach to specifying l1
would be to set (l1 + 1) as the smallest N1 such that if adaptations to recruitment were made at time
t1, the value of η needed to ensure that the posterior predictive probability ξ = pr{T ≤ 1.25 tp | η,N1}
exceeded 0.8 is considered feasible; here ξ would be calculated assuming the trial would always progress
to completion at time t2. The remaining boundaries u1 and u2 would then be fixed by constraints (D1) and
(D2). Fixing l1 in this manner implies that if the trial reaches the first interim analysis with N1 = l1, we
would conclude that an infeasibly large boost to recruitment is needed to ensure the risk of a significant
overrun remains acceptable. Of course, the trialist and funder would need to pre-specify what boost to the
average monthly recruitment rate would be considered infeasible. However, the direct interpretation of
l1 may prove helpful for trialists seeking to understand why their trial has been abandoned at the earliest
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Figure 5. Properties of Rules NERVES, localopt and globalopt : a) Conditional probability of progressing to
the main trial at time t2 to complete recruitment given we proceed to Stage 2 of the pilot study; b) Probability of
completing recruitment; c) Expected number of patients recruited by time tp for studies progressing to the
main trial to complete recruitment; d) Probability that the trial duration exceeds tp by more than 25%. All
evaluations set c1 = 2, c2 = 4, C = 6, nmax = 200 and tp = 17.3. Expected numbers recruited are based on
10 million simulations. Rule localopt is defined with (l1 = 17, u1 = 25, u2 = 48) while Rule globalopt is defined
with (l1 = 7, u1 = 15, u2 = 66).
opportunity.
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Throughout we have restricted attention to two-stage designs, assuming that the timeframe of most
trials will not allow for the implementation and assessment of multiple adaptations to recruitment.
However, this may be feasible and desirable in long-term trials with a recruitment period lasting several
years. To extend our approach to this setting, additional constraints would be needed to ensure unique
optimal designs exist. On another note, the pattern of centre opening times envisaged in Figure 1 tacitly
assumes that the option of boosting recruitment by opening extra centres is unavailable. However, it
would be straightforward to extend our framework to accommodate this case, the only change being
that we would anticipate recruiting across different numbers of centres should the trial progress with
adaptations and without them.
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